Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated
A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.
Therapeutic Area
Therapeutic area intelligence for Pancreatic Ductal Adenocarcinoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.